Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 1
A Phase 1/2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleuce…
Warm Autoimmune Hemolytic Anemia (WAIHA)ITP - Immune ThrombocytopeniaWarm Autoimmune Hemolytic Anemia+1 more
Estimated
~$10 – $8,750
CRISPR Therapeutics AGNCT07549698
Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads…
Immune Thrombocytopenic Purpura (ITP)
Estimated
~$10 – $7,500
TakedaNCT06722235
Phase 3
A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads…
Immune Thrombocytopenic Purpura (ITP)
Estimated
~$10 – $7,500
TakedaNCT06948318
Phase 1
The Use of Dose Dense Rituximab for High Risk Patients With Newly Diagnosed Acute Immune Thrombocytopenic Purpura
The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determ…
Immune Thrombocytopenic Purpura
Estimated
~$10 – $6,250
New York Medical CollegeNCT04323748